3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
3
Completed
3
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
90
Lung Neoplasms
34
Meningeal Carcinomatosis
11
Neoplasms
9
Neoplasm Metastasis
7
Adenocarcinoma of Lung
6
Colorectal Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Mesothelioma, Malignant
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Mesothelioma
3
Carcinoma
3
Advanced Solid Tumors
3
Non Squamous Non Small Cell Lung Cancer
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Breast Neoplasms
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
Pemetrexed
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled